1. Home
  2. TMTS vs PROF Comparison

TMTS vs PROF Comparison

Compare TMTS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spartacus Acquisition Corp. II Class A Ordinary Shares

TMTS

Spartacus Acquisition Corp. II Class A Ordinary Shares

N/A

Current Price

$10.02

Market Cap

308.7M

Sector

N/A

ML Signal

N/A

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$5.80

Market Cap

248.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMTS
PROF
Founded
2025
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
308.7M
248.8M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
TMTS
PROF
Price
$10.02
$5.80
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $11.14
AVG Volume (30 Days)
★ 306.1K
258.9K
Earning Date
N/A
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.89
EPS
★ N/A
N/A
Revenue
N/A
★ $16,098,000.00
Revenue This Year
N/A
$71.10
Revenue Next Year
N/A
$58.54
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 50.73
52 Week Low
$9.99
$4.91
52 Week High
$10.09
$8.95

Technical Indicators

Market Signals
Indicator
TMTS
PROF
Relative Strength Index (RSI) 50.25 46.38
Support Level N/A $5.65
Resistance Level $10.04 $6.23
Average True Range (ATR) 0.01 0.34
MACD -0.00 -0.04
Stochastic Oscillator 66.67 21.28

Price Performance

Historical Comparison
TMTS
PROF

About TMTS Spartacus Acquisition Corp. II Class A Ordinary Shares

Spartacus Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: